Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4322406 | 0.82 | PNMT (0.41) | — | |
| Hydrochloric Acid SCHEMBL21753155 | 0.82 | PNMT (0.41) | — | |
| Trifluoroacetic Acid SCHEMBL30321315 | 0.81 | UHRF1 (0.31) | — | |
| Hydrochloric Acid SCHEMBL30321390 | 0.79 | HTR2A (0.34) | — | |
| Hydrochloric Acid SCHEMBL31516219 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL31516210 | 0.79 | — | — | |
| SCHEMBL7935912 | 0.79 | PNMT (0.42) | — | |
| SCHEMBL31576135 | 0.77 | — | — | |
| SCHEMBL31576132 | 0.77 | — | — | |
| SCHEMBL28654615 | 0.77 | HTR2A (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113788834-B | 2,4-dichloro-6,7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine hydrochloride preparation method | 河南奥思恩医药科技有限公司 | 2022-11-29 | — | — | CN | claimed |
| CN-113788834-A | Preparation method of 2, 4-dichloro-6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine hydrochloride | 奥思恩(河南)新材料科技有限公司 | 2021-12-14 | — | — | CN | claimed |
| US-12630552-B2 | Inhibitors of KRAS G12C | BEONE MEDICINES I GMBH (CH) | 2026-05-19 | — | — | US | disclosed |
| WO-2024260386-A1 | MUSCARINIC M4 RECEPTOR AGONIST AND USE THEREOF | 西藏海思科制药有限公司 | 2024-12-26 | — | — | WO | disclosed |
| US-20230096028-A1 | BICYCLIC HETEROCYCLYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2023-03-30 | — | — | US | disclosed |
| US-20220389021-A1 | INHIBITORS OF KRAS G12C | BEONE MEDICINES I GMBH (CH) | 2022-12-08 | — | — | US | disclosed |
| CN-113788834-B | 2,4-dichloro-6,7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine hydrochloride preparation method | 河南奥思恩医药科技有限公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-113788834-B | 2,4-dichloro-6,7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine hydrochloride preparation method | 河南奥思恩医药科技有限公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-113788834-B | 2,4-dichloro-6,7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine hydrochloride preparation method | 河南奥思恩医药科技有限公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-114929706-A | Inhibitors of KRAS G12C | 百济神州有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022067462-A1 | PROCESS FOR PREPARING INHIBITORS OF KRAS G12C | BEIGENE (BEIJING) CO., LTD. (CN) | 2022-04-07 | — | — | WO | disclosed |
| EP-3930845-A1 | BICYCLIC HETEROCYCLYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| CN-113788834-A | Preparation method of 2, 4-dichloro-6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine hydrochloride | 奥思恩(河南)新材料科技有限公司 | 2021-12-14 | — | — | CN | disclosed |
| CN-113788834-A | Preparation method of 2, 4-dichloro-6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine hydrochloride | 奥思恩(河南)新材料科技有限公司 | 2021-12-14 | — | — | CN | disclosed |
| CN-113788834-A | Preparation method of 2, 4-dichloro-6, 7-dihydro-5H-pyrrolo [3,4-d ] pyrimidine hydrochloride | 奥思恩(河南)新材料科技有限公司 | 2021-12-14 | — | — | CN | disclosed |
| CN-113727758-A | Bicyclic heterocyclic compounds and use thereof | 锐新医药公司 | 2021-11-30 | — | — | CN | disclosed |
| US-7524852-B2 | Bicyclic pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1552842-A1 | BICYCLIC PYRIMIDINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |